Jin Medical International Ltd. (ZJYL) Stock Price & Analysis

Jin Medical International Ltd. (ZJYL) is trading at USD 3.42, up 1.33% today, as of November 18, 2026 at 15:02 UTC (US market open; quotes may be delayed), according to Nexqual market data.

ZJYL last closed at USD 3.38; today's session has ranged USD 3.29–3.44 on volume of 1,843 shares. Market capitalization is $544.45M, with a 52-week range of USD 1.53–5.6 (NCM). Source: Nexqual, retrieved November 18, 2026 at 19:41 UTC.

What changed for ZJYL since Aug 31, 2025

The built-in knowledge of several widely used AI models ends around Aug 31, 2025. Everything below is newer, dated and sourced (as of Nov 18, 2026).

Also available as compact Markdown for AI agents: nexqual.com/ZJYL.md

Key facts (ZJYL)

Analysts (ZJYL)

Consensus None.

Total return (dividends reinvested) (ZJYL)

1Y (from 2025-11-18)5Y (from 2023-03-27)
Total return-36.7%-54.1%
S&P 500 (SPY)+11.6%+66.1%
Per year-36.7%-19.2%
Volatility (annualized)112.1%161.9%
Max drawdown-66.5% (Nov 2025→Jul 2026)-99.3% (Jan 2024→Mar 2026)

Dividends (ZJYL)

ZJYL paid no cash dividend in the last five years.

Short interest (ZJYL)

7,541 shares sold short, 0.01% of the float, as of Oct 30, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 30, 2026): 70,013 shares (-89.2%). Days to cover: 0.0 (short shares ÷ average daily volume).

ZJYL major shareholder filing: Schedule 13D/A, Sep 25, 2026

Erqi Wang, JOLLY HARMONY ENTERPRISES Ltd filed a Schedule 13D/A with the SEC on Sep 25, 2026, reporting up to 3.35% of the class. A Schedule 13D is filed by an owner of more than 5% who may seek to influence the company. Item 4 (Purpose of Transaction), quoted from the filing:

The information set forth in Item 5 is hereby incorporated by reference into this Item 4. Item 4 is hereby amended and supplemented to add the following: This Amendment No. 1 is filed to report that the Reporting Persons' aggregate percentage beneficial ownership and voting power in the Issuer were diluted as a result of the Issuer's issuance of shares as described in Item 5 below.

Source: SEC EDGAR, Schedule 13D/A filed Sep 25, 2026. Quoted word for word; Nexqual adds no interpretation.

ZJYL recent SEC filings (last 120 days)

FiledFormWhat it says
Oct 30, 20266-KCurrent report (foreign issuer) · period ended Oct 30, 2026
Sep 25, 2026Schedule 13D/AErqi Wang, JOLLY HARMONY ENTERPRISES Ltd: 3.4% of shares, 5%+ holder that may seek to influence the company (amended)
“The information set forth in Item 5 is hereby incorporated by reference into this Item 4. Item 4 is hereby amended and supplemented to add the following: This Amendment No. 1 is filed to report that the Reporting Persons' aggregate percentage beneficial ownership and voting…”
Sep 24, 20266-KCurrent report (foreign issuer) · period ended Sep 24, 2026
Sep 8, 20266-KCurrent report (foreign issuer) · period ended Sep 8, 2026
Aug 21, 2026Schedule 13DWang Erqi, JOLLY HARMONY ENTERPRISES Ltd: 6.8% of shares, 5%+ holder that may seek to influence the company
“The information set forth in or incorporated by reference into Item 3 of this Schedule 13D is hereby incorporated by reference in its entirety into this Item 4. The transactions described in Item 3 were undertaken in connection with the Issuer's recapitalization and its…”
Aug 18, 2026Schedule 13GNOVASTRALIST HORIZON LTD., Chang Gil LEE: 10.5% of shares, passive 5%+ holder
Aug 4, 20266-KCurrent report (foreign issuer) · period ended Mar 31, 2026

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

ZJYL suppliers, customers and competitors (named in its 20-F)

RelationshipCompanySentence in the filing
CustomerNissin Medical Industries“We have one large customer, Nissin, with whom we generated substantial revenue each year.”

Quoted from the company's 20-F filed Feb 10, 2026.

ZJYL analyst estimates and revisions

PeriodEPS estimate90 days agoChangeRevenue estimateAnalysts
Current quarter———$0—
Next quarter———$0—
Current fiscal year———$0—
Next fiscal year———$0—

Key Statistics (as of November 18, 2026 at 19:41 UTC)

PriceUSD 3.42
Change▲ 1.33% (up)
Previous CloseUSD 3.38
OpenUSD 3.29
Day RangeUSD 3.29 – 3.44
52-Week RangeUSD 1.53 – 5.6
Volume1,843 shares
Market Cap$544.45M
ExchangeNCM

Technical Analysis (ZJYL)

Nexqual's technical model rates ZJYL "STRONG BUY" based on 5 bullish and 0 bearish signals across 129 daily candles, as of November 18, 2026 at 19:41 UTC.

Overall SignalSTRONG BUY
RSI (14)56.86 (neutral)
vs SMA50Above (USD 2.41)
MACD0.42 (positive)

Analyst Ratings (ZJYL)

Wall Street analysts rate ZJYL "None", per Nexqual as of November 18, 2026 at 19:41 UTC.

Consensus RatingNone

Earnings (ZJYL)

Source: Nexqual, November 18, 2026 at 19:41 UTC.

Financials & Fundamentals (ZJYL)

Total Revenue$19.73M
Revenue Growth (latest quarter, YoY)-9.70%
Gross Margin+31.28%
Operating Margin+2.12%
Profit Margin+5.95%
ROE+4.02%
Debt / Equity0.69
Current Ratio1.95
Total Cash$30.10M
Total Debt$20.90M

Source: Nexqual, November 18, 2026 at 19:41 UTC.

Financial Health Score (ZJYL)

Nexqual rates Jin Medical International Ltd.'s overall financial health "Weak" across five dimensions, as of November 18, 2026 at 19:41 UTC.

GrowthWeak — Revenue -10% YoY (latest Q), declining
ProfitabilityWeak — Small revenue base — building scale
Balance SheetSolid — $30M cash vs $21M debt, net cash position
Cash FlowWeak — Operating cash flow -$593K (TTM)
EfficiencyWeak — ROE 4%, ROA 0.5%

Ownership (ZJYL)

Insider Ownership+11.97%
Institutional Ownership+0.00%
Shares Outstanding153.43M
Float64.84M
Short % of Float+0.01%

Source: Nexqual, November 18, 2026 at 19:41 UTC.

Leadership (ZJYL)

Jin Medical International Ltd. is led by Erqi Wang, Chairman of the Board, President & CEO, per Nexqual as of November 18, 2026 at 19:41 UTC.

Chairman of the Board, President & CEOErqi Wang
CFO & DirectorZiqiang Wang

Peers & Related Stocks

SymbolNamePriceChange
LMATLeMaitre Vascular, Inc.USD 75.59▼ 0.68%
AZTAAzenta, Inc.USD 47.5▲ 3.68%
ATRCAtriCure, Inc.USD 55.83▲ 1.46%
VVVVvVARDIS Holding AGUSD 15.67▼ 0.85%
WRBYWarby Parker Inc.USD 26.09▲ 0.66%
PLSEPulse Biosciences, IncUSD 44.6▼ 0.54%

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: November 18, 2026 at 19:41 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt